ScienceTechyNews: Icosapent ethyl drug reduces risk of recurrent cardiovascular events

6:27 AM
Further insights from the REDUCE-IT trial show that high-dose, pure and stable EPA omega 3 drug not only reduces the burden of first cardiovascular events but also subsequent and total heart attacks, strokes, and other measures.

by

Post a Comment

No comments

Subscribe to: Post Comments ( Atom )
Powered by Blogger.